Overview of ALK and ROS1 rearranged lung cancer

Tuberculosis and Respiratory Diseases

Volumn 75, Issue 6, 2013, Pages 236-237

  Choi, Chang Min ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Anplastic Lymphoma Kinase; Lung Neoplasms; ROS1 Protein, Human

Indexed keywords

ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; AP 26113; CERITINIB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; IMATINIB; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; [2 [[5 CHLORO 2 [[4 [4 (DIMETHYLAMINO) 1 PIPERIDINYL] 2 METHOXYPHENYL]AMINO] 4 PYRIMIDINYL]AMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR;

CARCINOGENESIS; CONSTIPATION; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENE REARRANGEMENT; HUMAN; INTERSTITIAL PNEUMONIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; NAUSEA; ONCOGENE; REVIEW; TREATMENT RESPONSE; VISUAL DISORDER; VOMITING; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; ONCOGENE C ROS 1; PHASE 1 CLINICAL TRIAL (TOPIC);

EID: 84922803165     PISSN: 17383536     EISSN: None     Source Type: Journal    
DOI: 10.4046/trd.2013.75.6.236     Document Type: Review

References (5)

1. Soda M, Choi YL, E nomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6.
2. Doebele RC, Camidge DR . Targeting ALK, ROS1, and BRAF kinases. J Thorac Oncol 2012;7(16 Suppl 5):S375-6.
3. Paik JH, Choi CM, Kim H, Jang SJ, Choe G, Kim DK, et al. Clinicopathologic implication of AL K rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer 2012;76:403-9.
4. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solo mon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
5. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010;363:1734-9.